---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-019607"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T01:57:38.631504+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M

## Summary
- Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.
- 2024 revenue guidance raised to $620-650M from $600-630M.
- Cash and investments $451.0M at March 31, 2024.
- GRACE open-label phase showed significant improvements; NDA for relacorilant in Cushing's expected this quarter.
- Enrollment completed in GRADIENT, CATALYST, ROSELLA, DAZALS; data expected by year-end.

## SEC filing metadata
- accession: 0001628280-24-019607
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828024019607/0001628280-24-019607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828024019607/cort-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-019607
- JSON: https://secwatch.observer/filing/0001628280-24-019607.json
- Plain text: https://secwatch.observer/filing/0001628280-24-019607.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.